Gland Pharma – Multiple Levers At Play; Valuations Attractive: Motilal Oswal


BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

After delivering 27% earnings compound annual growth rate over FY17-22, Gland Pharma Ltd. is well-placed to sustain its earnings growth momentum over the next three-to-five years.

It has been enhancing its offerings by adding complex products to its portfolio, scaling the product at the global level, expanding capacity to aid manufacturing, as well as increased backward integration.

While constraints on availability of certain materials may hinder performance over the near term, Gland Pharma is in good stead for consistent performance over the next three-to-five years.

The 40% correction over the past 10-12 months, despite healthy earnings growth, provides sufficient cushion on the valuation front.

Click on the attachment to read the full report:


This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.


Source link

What is your reaction?

In Love
Not Sure

You may also like

Comments are closed.

More in:Business